Demand for drugs drives up profits at Novartis

Novartis has revealed strong first-half results, fuelled by demand for its hypertension, osteoporosis and asthma drugs.

Demand for drugs drives up profits at Novartis

Novartis has revealed strong first-half results, fuelled by demand for its hypertension, osteoporosis and asthma drugs.

Europe's third-largest pharmaceuticals company says operating profit rose 7% in the first-half as demand for its hypertension treatment Diovan accelerated.

Already a subscriber? Sign in

You have reached your article limit.

Unlimited access. Half the price.

Annual €130 €65

Best value

Monthly €12€6 / month

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited